Physician profile
Tammy S Parrett
NPI 1699706028
$12,235.03
in general payments reported to CMS, 2019-2025
37 companies · $3,233 in 2025
The $3,233 reported for 2025 was more than what 97% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,130 · 2022: $2,268 · 2023: $2,574 · 2024: $3,030 · 2025: $3,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,510 · Travel and Lodging: $255 · Education: $72.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,509.55 |
| Travel and Lodging | $255.15 |
| Education | $72.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,762.23 | 2021-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $1,684.62 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| United Therapeutics Corporation | $1,523.95 | 2021-2025 | Tyvaso, Tyvaso, Steen Solution |
| Boehringer Ingelheim Pharmaceuticals, INC. | $945.29 | 2021-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Mylan Specialty L.P. | $612.89 | 2021-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $566.70 | 2021-2025 | Dupixent |
| Verona Pharma, INC. | $531.29 | 2025 | Ohtuvayre |
| Genzyme Corporation | $523.81 | 2021-2025 | |
| Insmed, INC. | $440.36 | 2021-2025 | Arikayce, Brinsupri |
| Novartis Pharmaceuticals Corporation | $385.84 | 2021-2025 | |
| Vifor Pharma, INC. | $385.56 | 2024-2025 | Zemaira, Veltassa |
| Viatris Specialty LLC | $384.60 | 2025 | Yupelri |
| Amgen INC. | $365.04 | 2021-2025 | Tezspire, Lumakras |
| Inspire Medical Systems, INC. | $299.35 | 2024-2025 | Inspire |
| Abbvie INC. | $288.34 | 2021-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $271.83 | 2021-2025 | Zerbaxa, Dificid, Winrevair |
| Actelion Pharmaceuticals US, INC. | $257.34 | 2022-2025 | Opsumit, Uptravi, Opsynvi |
| Takeda Pharmaceuticals U.S.A., INC. | $219.47 | 2021-2025 | Glassia |
| Baxter Healthcare | $156.87 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Electromed, INC. | $133.69 | 2022-2024 | Smartvest |
| Mallinckrodt Hospital Products INC. | $79.49 | 2022-2023 | Acthar |
| Genentech USA, INC. | $77.89 | 2021-2024 | Xolair |
| Shionogi INC | $57.41 | 2022-2024 | Fetroja |
| Avadel Cns Pharmaceuticals, LLC | $33.88 | 2024-2025 | Lumryz |
| Pfizer INC. | $32.39 | 2024 | |
| Harmony Biosciences LLC | $31.70 | 2025 | |
| Lilly USA, LLC | $24.78 | 2025 | Zepbound |
| Csl Behring | $23.86 | 2025 | Hizentra |
| Grifols USA, LLC | $19.78 | 2022 | |
| La Jolla Pharmaceutical Company | $18.14 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.50 | 2025 | |
| Ani Pharmaceuticals, INC. | $16.48 | 2022 | |
| Inogen, INC. | $13.65 | 2025 | |
| Medtronic, INC. | $13.15 | 2023 | Endurant Iis |
| Idorsia Pharmaceuticals US INC | $12.72 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $12.19 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Parrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.